Zelenskyy says he is open to elections if U.S. ensures security
Ukrainian President Volodymyr Zelenskyy said on Tuesday he was prepared to hold elections within three months if the U.S. and Kyiv's other allies coul...
French pharmaceutical giant Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines for $9.1 billion to strengthen its portfolio in rare immunological diseases.
France-based pharmaceutical company Sanofi announced Monday that it will acquire U.S.-based Blueprint Medicines Corporation for $9.1 billion, in a strategic move to bolster its presence in rare immunological diseases.
Blueprint, a biopharmaceutical company specializing in systemic mastocytosis (SM) and other KIT-driven diseases, accepted Sanofi’s offer of $129 per share in cash. The offer represents a 27% premium over Blueprint’s last closing price of $101.35 on Friday.
The acquisition includes Ayvakit (avapritinib), a treatment for SM approved in both the U.S. and EU, along with a robust early- and late-stage immunology pipeline.
“Blueprint’s established relationships with allergists, dermatologists, and immunologists are expected to enhance Sanofi’s growing immunology portfolio,” the French company said in a statement.
The transaction is expected to close in the third quarter of 2025, pending regulatory approvals.
As part of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), entitling them to potential milestone payments of $2 and $4 per CVR based on future achievements.
Blueprint is currently the only company with an approved drug for systemic mastocytosis - a rare disorder caused by excess mast cells - and is also developing next-generation therapies for SM and other immune disorders.
The acquisition marks the largest healthcare M&A deal in Europe so far this year. It follows Sanofi’s recent purchase of Vigil Neuroscience for $470 million last month - the second time the French company has acquired Vigil in 2025, after an initial purchase in January.
Authorities in Japan lifted all tsunami warnings on Tuesday following a strong 7.5-magnitude earthquake that struck off the northeastern coast late on Monday, injuring at least 30 people and forcing around 90,000 residents to evacuate their homes.
Pressure is mounting between Venezuela and the United States as both nations emphasise military preparedness and strategic positioning.
A group of demonstrators gathered outside the Norwegian Nobel Institute to protest the awarding of this year’s Nobel Peace Prize.
Tehran has protested to Washington because of the travel ban on its football team delegation as well as Iranian fans who would like to travel to the United States for the upcoming World Cup matches in 2026.
Paramount Skydance (PSKY.O) has launched a $108.4 billion hostile takeover bid for Warner Bros Discovery (WBD.O). The escalation follows a high-stakes battle that had appeared to end last week when Netflix secured a $72 billion deal for the studio giant’s assets.
A viral claim circulating online that Denmark requires sperm donors to have an IQ of at least 85 is misleading. While one Danish sperm bank, Donor Network, does use an IQ threshold, there is no nationwide legal requirement for donors to meet a specific level of intelligence.
Chinese scientists have unveiled a new gene-editing therapy that they say could lead to a functional cure for HIV, making it one of the most promising developments in decades of global research.
The Democratic Republic of the Congo (DRC) has declared the end of a 16th Ebola outbreak, closing a two month emergency in Kasai Province that pushed national and international teams into an intensive response.
The U.S. Food and Drug Administration Commissioner Marty Makary said on Saturday that data showed 10 children had died because of COVID-19 vaccination shots.
The Spanish agricultural sector has been placed on high alert following the confirmation that African Swine Fever (ASF) has resurfaced in the country for the first time in over thirty years.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment